|
Eine Ebene nach oben |
Gruppiert nach: Dokumententyp |
Veröffentlichungsdatum
Anzahl der Publikationen: 12
2022
Fischer, Laura E. 
ORCID: https://orcid.org/0000-0001-8752-5827; Stintzing, Sebastian; Weikersthal, Ludwig Fischer von; Modest, Dominik P.; Decker, Thomas; Kiani, Alexander ORCID: https://orcid.org/0000-0002-2494-4087; Kaiser, Florian; Al-Batran, Salah-Eddin; Heintges, Tobias; Lerchenmüller, Christian; Kahl, Christoph; Seipelt, Gernot; Kullmann, Frank; Stauch, Martina; Scheithauer, Werner; Giessen-Jung, Clemens; Uhlig, Jens; Peuser, Bettina; Denzlinger, Claudio; Stahler, Arndt; Weiss, Lena; Heinrich, Kathrin; Held, Swantje; Jung, Andreas; Kirchner, Thomas und Heinemann, Volker
(2022):
Efficacy of FOLFIRI plus cetuximab vs FOLFIRI plus bevacizumab in 1st-line treatment of older patients with RAS wild-type metastatic colorectal cancer: an analysis of the randomised trial FIRE-3.
In: British Journal of Cancer, Bd. 127, Nr. 5: S. 836-843
[PDF, 788kB]
ORCID: https://orcid.org/0000-0001-8752-5827; Stintzing, Sebastian; Weikersthal, Ludwig Fischer von; Modest, Dominik P.; Decker, Thomas; Kiani, Alexander ORCID: https://orcid.org/0000-0002-2494-4087; Kaiser, Florian; Al-Batran, Salah-Eddin; Heintges, Tobias; Lerchenmüller, Christian; Kahl, Christoph; Seipelt, Gernot; Kullmann, Frank; Stauch, Martina; Scheithauer, Werner; Giessen-Jung, Clemens; Uhlig, Jens; Peuser, Bettina; Denzlinger, Claudio; Stahler, Arndt; Weiss, Lena; Heinrich, Kathrin; Held, Swantje; Jung, Andreas; Kirchner, Thomas und Heinemann, Volker
(2022):
Efficacy of FOLFIRI plus cetuximab vs FOLFIRI plus bevacizumab in 1st-line treatment of older patients with RAS wild-type metastatic colorectal cancer: an analysis of the randomised trial FIRE-3.
In: British Journal of Cancer, Bd. 127, Nr. 5: S. 836-843
[PDF, 788kB]
Hofheinz, Ralf-Dieter; Merx, Kirsten; Haag, Georg M.; Springfeld, Christoph; Ettrich, Thomas; Borchert, Kersten; Kretzschmar, Albrecht; Teschendorf, Christian; Siegler, Gabriele; Ebert, Matthias P.; Goekkurt, Eray; Mahlberg, Rolf; Homann, Nils; Pink, Daniel; Bechstein, Wolf; Reichardt, Peter; Flach, Hagen; Gaiser, Timo; Battmann, Achim; Oduncu, Fuat S.; Loose, Maria; Sookthai, Disorn; Pauligk, Claudia; Goetze, Thorsten O. und Al-Batran, Salah-Eddin
(2022):
FLOT Versus FLOT/Trastuzumab/Pertuzumab Perioperative Therapy of Human Epidermal Growth Factor Receptor 2-Positive Resectable Esophagogastric Adenocarcinoma: A Randomized Phase II Trial of the AIO EGA Study Group.
In: Journal of Clinical Oncology, Bd. 40, Nr. 32: S. 3750-3762
2020
Joensuu, Heikki; Eriksson, Mikael; Hall, Kirsten Sundby; Reichardt, Annette; Hermes, Barbara; Schuette, Jochen; Cameron, Silke; Hohenberger, Peter; Jost, Philipp J.; Al-Batran, Salah-Eddin; Lindner, Lars H.; Bauer, Sebastian; Wardelmann, Eva; Nilsson, Bengt; Kallio, Raija; Jaakkola, Panu; Junnila, Jouni; Alvegard, Thor und Reichardt, Peter
(2020):
Survival Outcomes Associated With 3 Years vs 1 Year of Adjuvant Imatinib for Patients With High-Risk Gastrointestinal Stromal Tumors An Analysis of a Randomized Clinical Trial After 10-Year Follow-up.
In: Jama Oncology, Bd. 6, Nr. 8: S. 1241-1246
2019
Al-Batran, Salah-Eddin; Homann, Nils; Pauligk, Claudia; Götze, Thorsten O.; Meiler, Johannes; Kasper, Stefan; Kopp, Hans-Georg; Mayer, Frank; Haag, Georg Martin; Luley, Kim; Lindig, Udo; Schmiegel, Wolff; Pohl, Michael; Stoehlmacher, Jan; Folprecht, Gunnar; Probst, Stephan; Prasnikar, Nicole; Fischbach, Wolfgang; Mahlberg, Rolf; Trojan, Jörg; Königsmann, Michael; Martens, Uwe M.; Thuss-Patience, Peter; Egger, Matthias; Block, Andreas; Heinemann, Volker; Illerhaus, Gerald; Moehler, Markus; Schenk, Michael; Kullmann, Frank; Behringer, Dirk M.; Heike, Michael; Pink, Daniel; Teschendorf, Christian; Loehr, Carmen; Bernhard, Helga; Schuch, Gunter; Rethwisch, Volker; Fischer von Weikersthal, Ludwig; Hartmann, Jörg T.; Kneba, Michael; Daum, Severin; Schulmann, Karsten; Weniger, Jörg; Belle, Sebastian; Gaiser, Timo; Oduncu, Fuat S.; Guentner, Martina; Hozaeel, Wael; Reichart, Alexander; Jaeger, Elke; Kraus, Thomas; Moenig, Stefan; Bechstein, Wolf O.; Schuler, Martin; Schmalenberg, Harald und Hofheinz, Ralf D.
(2019):
Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial.
In: Lancet, Bd. 393, Nr. 10184: S. 1948-1957
Gaiser, Maria R.; Lorenzen, Sylvie; Merx, Kirsten; Trojan, Jörg; Ocvirk, Janja; Ettrich, Thomas J.; Al-Batran, Salah-Eddin; Schulz, Holger; Homann, Nils; Feustel, Hans-Peter; Schatz, Michael; Kripp, Melanie; Schulte, Nadine; Heeger, Steffen; Vlassak, Soetkin; Koch, Winfried und Hofheinz, Ralf-Dieter
(2019):
Evaluation of EGFR inhibitor-mediated acneiform skin toxicity within the double-blind randomized EVITA trial: A thorough gender-specific analysis using the WoMo score.
In: Cancer Medicine, Bd. 8, Nr. 9: S. 4169-4175
2017
Lordick, Florian; Al-Batran, Salah-Eddin; Dietel, Manfred; Gaiser, Timo; Hofheinz, Ralf-Dieter; Kirchner, Thomas; Kreipe, Hans H.; Lorenzen, Sylvie; Möhler, Markus; Quaas, Alexander; Röcken, Christoph; Rüschoff, Josef; Tannapfel, Andrea; Thuss-Patience, Peter und Baretton, Gustavo
(2017):
HER2 testing in gastric cancer: results of a German expert meeting.
In: Journal of Cancer Research and Clinical Oncology, Bd. 143, Nr. 5: S. 835-841
Modest, Dominik P.; Stintzing, Sebastian; Fischer von Weikersthal, Ludwig; Decker, Thomas; Kiani, Alexander; Vehling-Kaiser, Ursula; Al-Batran, Salah-Eddin; Heintges, Tobias; Lerchenmüller, Christian; Kahl, Christoph; Seipelt, Gernot; Kullmann, Frank; Scheithauer, Werner; Kirchner, Thomas; Jung, Andreas; Stauch, Martina; Einem, Jobst Christian von; Möhler, Markus; Held, Swantje und Heinemann, Volker
(2017):
Relation of early tumor shrinkage (ETS) observed in first-line treatment to efficacy parameters of subsequent treatment in FIRE-3 (AIOKRK0306).
In: International Journal of Cancer, Bd. 140, Nr. 8: S. 1918-1925
Harbeck, Nadia; Saupe, Steffen; Jäger, Elke; Schmidt, Marcus; Kreienberg, Rolf; Müller, Lothar; Otremba, Burkhard Jörg; Waldenmaier, Dirk; Dorn, Julia; Warm, Mathias; Scholz, Michael; Untch, Michael; Wit, Maike de; Barinoff, Jana; Lück, Hans-Joachim; Harter, Philipp; Augustin, Doris; Harnett, Paul; Beckmann, Matthias W. und Al-Batran, Salah-Eddin
(2017):
A randomized phase III study evaluating pegylated liposomal doxorubicin versus capecitabine as first-line therapy for metastatic breast cancer: results of the PELICAN study.
In: Breast Cancer Research and Treatment, Bd. 161, Nr. 1: S. 63-72
[PDF, 711kB]
Joensuu, Heikki; Wardelmann, Eva; Sihto, Harri; Eriksson, Mikael; Hall, Kirsten Sundby; Reichardt, Annette; Hartmann, Jörg T.; Pink, Daniel; Cameron, Silke; Hohenberger, Peter; Al-Batran, Salah-Eddin; Schlemmer, Marcus; Bauer, Sebastian; Nilsson, Bengt; Kallio, Raija; Junnila, Jouni; Vehtari, Aki und Reichardt, Peter
(2017):
Effect of KIT and PDGFRA Mutations on Survival in Patients With Gastrointestinal Stromal Tumors Treated With Adjuvant Imatinib An Exploratory Analysis of a Randomized Clinical Trial.
In: Jama Oncology, Bd. 3, Nr. 5: S. 602-609
2016
Joensuu, Heikki; Eriksson, Mikael; Hall, Kirsten Sundby; Reichardt, Annette; Hartmann, Jörg T.; Pink, Daniel; Ramadori, Giuliano; Hohenberger, Peter; Al-Batran, Salah-Eddin; Schlemmer, Marcus; Bauer, Sebastian; Wardelmann, Eva; Nilsson, Bengt; Sihto, Harri; Bono, Petri; Kallio, Raija; Junnila, Jouni; Alvegård, Thor und Reichardt, Peter
(2016):
Adjuvant Imatinib for High-Risk GI Stromal Tumor: Analysis of a Randomized Trial.
In: Journal of Clinical Oncology, Bd. 34, Nr. 3:
244-U99
Modest, Dominik Paul; Stintzing, Sebastian; Fischer von Weikersthal, Ludwig; Sobrero, Alberto F.; Decker, Thomas; Kiani, Alexander; Vehling-Kaiser, Ursula; Al-Batran, Salah-Eddin; Heintges, Tobias; Seipelt, Gernot; Lerchenmüller, Christian A.; Kahl, Christoph; Kullmann, Frank; Stauch, Martina; Scheithauer, Werner; Held, Swantje; Moehler, Markus H.; Jung, Andreas; Kirchner, Thomas und Heinemann, Volker
(2016):
Time-course evaluation of survival and treatment in FIRE-3 (AIO KRK0306, first-line therapy of KRAS wild-type metastatic colorectal cancer with FOLFIRI plus cetuximab or bevacizumab).
In: Journal of Clinical Oncology, Bd. 34, Nr. 4
Stintzing, Sebastian; Modest, Dominik P.; Rossius, Lisa; Lerch, Markus M.; Fischer von Weikersthal, Ludwig; Decker, Thomas; Kiani, Alexander; Vehling-Kaiser, Ursula; Al-Batran, Salah-Eddin; Heintges, Tobias; Lerchenmüller, Christian; Kahl, Christoph; Seipelt, Gernot; Kullmann, Frank; Stauch, Martina; Scheithauer, Werner; Held, Swantje; Giessen-Jung, Clemens; Moehler, Markus; Jagenburg, Andreas; Kirchner, Thomas; Jung, Andreas und Heinemann, Volker
(2016):
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): a post-hoc analysis of tumour dynamics in the final RAS wild-type subgroup of this randomised open-label phase 3 trial.
In: Lancet Oncology, Bd. 17, Nr. 10: S. 1426-1434